Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation
| Autor: | Linda J. Burns, Astrid Andreescu, David P. Steensma, Erica D. Warlick, Anthony F. Bonagura, Daniel F. Pease, Mark B. Juckett, Virginia M. Klimek, Nandita Khera, Celalettin Ustun, Tamila L. Kindwall-Keller, Mary M. Horowitz, Andrew M. Brunner, Bryce M. Waldman, Abhinav B. Chandra, James M. Foran |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty Transplantation Conditioning business.industry Myelodysplastic syndromes Ethnic group Hematopoietic Stem Cell Transplantation medicine.disease Patient advocacy Article Clinical trial Transplantation surgical procedures operative Oncology Bone transplantation Bone Marrow hemic and lymphatic diseases Expanded access Myelodysplastic Syndromes Health care medicine Humans Transplantation Homologous Intensive care medicine business |
| Zdroj: | Cancer |
| ISSN: | 1097-0142 |
| Popis: | LAY SUMMARY People who have advanced myelodysplastic syndromes (MDS) may live longer if they get a bone marrow transplant (BMT) instead of other therapies. However, only 15% of people with MDS actually get BMT. Experts say community physicians and transplant physicians should team up with insurance companies and patient advocacy groups to 1) spread this news about lifesaving advances in BMT, 2) ensure that everyone can afford health care, 3) provide emotional support for patients and families, 4) help patients and families get transportation and housing if they need to travel for transplant, and 5) improve care for people of under-represented racial and ethnic backgrounds. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text